lancet semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Semaglutide - Wikipedia

Both animal and human studies have shown that increased GLP-1 activity reduces intestinal motility [23]

So, regulators have been dubious about telehealth companies' claims that, in the case of Hims & Hers, nearly half a million patients need custom doses

Each guide clearly labels the evidence tier

The FLOW trial was a multinational, randomized controlled clinical trial in which 3533 adults with T2D and CKD were randomized in a 1:1 ratio to once-weekly semaglutide 1 mg or to placebo on top of standard care

Semaglutide, primarily recognized for its effectiveness in type 2 diabetes management and weight loss, may also play a significant role in immune regulation

Source Citations: GLP-1 diabetes and weight-loss drug side effects: "Ozempic face" and more